ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.62
0.96%
US Tech 100
18,064.80
0.02%
S&P 500
5,277.51
0.80%
US Dollar vs CAD
1.36525
-0.01%
Bitcoin
67,672.23
0.28%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Panbela Therapeutics Inc (PBLA)

  7. Panbela Therapeutics Inc (PBLA) News

PBLA

Panbela Therapeutics (PBLA)

Panbela Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PBLA
DateTimeSourceHeadlineSymbolCompany
05/29/20246:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
05/15/20243:10PMGlobeNewswire Inc.Panbela Provides Business Update and Reports Q1 2024 Financial ResultsNASDAQ:PBLAPanbela Therapeutics Inc
05/06/20247:00AMGlobeNewswire Inc.Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and SulindacNASDAQ:PBLAPanbela Therapeutics Inc
05/01/20243:15PMGlobeNewswire Inc.Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024NASDAQ:PBLAPanbela Therapeutics Inc
04/30/20247:00AMGlobeNewswire Inc.Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease WeekNASDAQ:PBLAPanbela Therapeutics Inc
04/26/20243:39PMEdgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:PBLAPanbela Therapeutics Inc
04/25/20243:36PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:PBLAPanbela Therapeutics Inc
04/25/20243:35PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
04/25/20248:09AMEdgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:PBLAPanbela Therapeutics Inc
04/22/20247:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
04/22/20247:00AMGlobeNewswire Inc.Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025NASDAQ:PBLAPanbela Therapeutics Inc
04/18/20243:31PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PBLAPanbela Therapeutics Inc
04/18/20247:00AMGlobeNewswire Inc.Panbela Announces Poster Presentation at American Association for Cancer Research:NASDAQ:PBLAPanbela Therapeutics Inc
04/17/20247:36AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
04/16/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PBLAPanbela Therapeutics Inc
04/16/20244:29PMGlobeNewswire Inc.Panbela Announces Transfer to OTCQB MarketNASDAQ:PBLAPanbela Therapeutics Inc
04/04/20243:17PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PBLAPanbela Therapeutics Inc
04/02/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PBLAPanbela Therapeutics Inc
03/29/20244:24PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PBLAPanbela Therapeutics Inc
03/29/20244:08PMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PBLAPanbela Therapeutics Inc
03/26/20243:15PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PBLAPanbela Therapeutics Inc
03/26/20243:12PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
03/26/20243:10PMGlobeNewswire Inc.Panbela Provides Business Update and Reports Q4 and FY 2024 Financial ResultsNASDAQ:PBLAPanbela Therapeutics Inc
03/26/20246:21AMIH Market NewsU.S. Index Futures on the Rise, Oil Prices Show StabilityNASDAQ:PBLAPanbela Therapeutics Inc
03/25/20243:15PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:PBLAPanbela Therapeutics Inc
03/12/20243:15PMGlobeNewswire Inc.Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024NASDAQ:PBLAPanbela Therapeutics Inc
03/07/20245:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
02/15/20247:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
02/15/20247:00AMGlobeNewswire Inc.Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares RequirementsNASDAQ:PBLAPanbela Therapeutics Inc
02/13/20247:10PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PBLAPanbela Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PBLA

Your Recent History

BIT
F21899
Vontobel Financial Produ...
BMF
DIFJ25N25
DIFJ25N25 - 04/2025
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved